MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Inolitazone

CAS No. : 223132-37-4

MCE 站：Inolitazone

产品活性：Inolitazone(RS5444; CS-7017)是新型PPARγ高亲和性激动剂，EC50为rosiglitazone的五十分，对于不表达PPARγ的RIE细胞无抑制性。

研究领域：Cell Cycle/DNA Damage

作用靶点：PPAR

In Vitro: Inolitazone (RS5444) upregulates the cell cycle kinase inhibitor, p21 ^WAF1/CIP1. Silencing p21 ^WAF1/CIP1 rendered cells insensitive to Inolitazone. A 10 nM dose of Inolitazone activates PPARγ:RXRα-dependent transcription as demonstrated in a transient transfection assay utilizing a PPRE response element fused to a luciferase reporter gene (PPRE3-tk-luc). DRO cells are treated in culture with Inolitazone, Rosiglitazone, or Troglitazone at the indicated concentrations. DRO cells are transiently transfected with PPRE3-tk-luc to examine effective concentrations at which EC₅₀ occurs. The EC₅₀s are 1 nM (Inolitazone), 65 nM (Rosiglitazone) and 631 nM (Troglitazone). Similarly, the calculated inhibitory concentration at IC₅₀ is 0.8 nM for Inolitazone, 75 nM for Rosiglitazone, and 1412 nM for Troglitazone. Inolitazone specifically activates PPARγ, but not PPARα or PPARδ. Exposure of 10 nM Inolitazone following transient transfection with the appropriate PPAR isoform (γ, α, or δ) and PPAR response element linked to a luciferase reporter in RIE rat small intestinal cell line, which does not express PPARs, yields increased luciferase activity only in the presence of PPARγ and PPRE3-tk-luc. DRO cells are growth inhibited by 10 nM Inolitazone (RS5444) through a PPARγ-dependent mechanism.

In Vivo: Inolitazone (RS5444) plus Paclitaxel demonstrate additive antiproliferative activity in cell culture and minimal ATC tumor growth. When Inolitazone is administered in the diet to athymic nude mice prior to DRO tumor cell implantation, tumor growth is inhibited in a dose responsive fashion. At the highest dose, 0.025% Inolitazone inhibits growth on day 32 by 94.4% as compared to that of control. In this treatment group, five of 10 animals do not develop demonstrable tumors. In the 0.0025% treatment group, tumor growth is inhibited by 62.3% compared to that of control on day 32 while the 0.00025% dose demonstrated no growth inhibitory activity as compared to control. Tumors is nest allowed to establish in the mouse and began 0.025% Inolitazone treatment of mice 1 week after DRO or ARO tumor cell implantation. Inolitazone treated animals demonstrate tumor growth inhibition of 68.9% in DRO tumors and 48.3% in ARO tumors as compared to that of their respective controls on day 35.

相关产品：Retinoic acid  |  Rosiglitazone  |  GW9662  |  GW6471  |  Pioglitazone  |  Fenofibrate  |  T0070907  |  Troglitazone  |  Fisetin  |  GW 501516  |  Pirinixic acid  |  5-Aminosalicylic Acid  |  Daidzein  |  GW1929  |  Naringenin  |  Icariin  |  MK-886  |  GW7647  |  Bezafibrate  |  GSK3787  |  GW0742  |  Astaxanthin  |  FH535  |  Magnolol  |  Gemfibrozil  |  Seladelpar sodium salt  |  Palmitelaidic Acid  |  Eupatilin

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。